Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Waldenström's macroglobulinaemia.

S A Johnson1, D G Oscier, V Leblond

  • 1Taunton & Somerset Hospital, Taunton, Somerset, UK. steve.johnson@tst.nhs.uk

Blood Reviews
|August 7, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights.

Leukemia·2026
Same author

Exposure to extrinsic stressors, social defeat or bisphenol A, eliminates sex differences in DNA methyltransferase expression in the amygdala.

Journal of neuroendocrinology·2017
Same author

Lessons learned from a multidisciplinary renal genetics clinic.

QJM : monthly journal of the Association of Physicians·2017
Same author

Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial.

Leukemia·2016
Same author

Mechanical strength vs. degradation of a biologically-derived surgical mesh over time in a rodent full thickness abdominal wall defect.

Biomaterials·2016
Same author

Effects of a maternal high-fat diet on offspring behavioral and metabolic parameters in a rodent model.

Journal of developmental origins of health and disease·2016
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Waldenström's macroglobulinaemia (WM) is a distinct B-cell lymphoproliferative disorder. Current treatments offer moderate response rates, but newer therapies like purine analogues and monoclonal antibodies show promise for improved outcomes in WM patients.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Waldenström's macroglobulinaemia (WM) is a chronic lymphoproliferative disorder characterized by a distinct B-cell phenotype and IgM paraprotein.
  • The clonal B-cells in WM originate from post-germinal center B-cells, exhibiting specific surface markers (IgM, CD19, CD20).
  • Historically, WM treatment relied on alkylating agents and corticosteroids, with plasmapheresis for hyperviscosity complications, yielding approximately 60% response rates and 60-month median survival.

Purpose of the Study:

  • To review the current understanding of Waldenström's macroglobulinaemia (WM) pathophysiology and treatment landscape.
  • To evaluate the efficacy of purine analogues and newer therapeutic agents in WM management.
  • To discuss the evolving treatment strategies and future directions for WM.

Related Experiment Videos

Main Methods:

  • Literature review of WM pathophysiology, diagnostic criteria, and treatment outcomes.
  • Analysis of data on traditional therapies (alkylating agents, corticosteroids, plasmapheresis).
  • Evaluation of emerging treatments including purine analogues (fludarabine, cladribine), monoclonal antibodies (rituximab), and transplant procedures.

Main Results:

  • Traditional WM treatment achieves ~60% response rates and ~60 months median survival.
  • Purine analogues show activity in alkylating agent-resistant WM and are being investigated as initial therapy.
  • Newer advances include rituximab and stem cell transplantation for selected WM patients.

Conclusions:

  • WM is a distinct B-cell malignancy with specific clinical and pathological features.
  • While traditional therapies have limitations, emerging treatments offer improved response rates and survival.
  • Ongoing research and clinical trials are crucial for optimizing WM patient outcomes.